ClinicalTrials.gg
TerminatedNCT04314843ZUMA-19Updated Mar 4, 2024Results posted

Study of Lenzilumab and Axicabtagene Ciloleucel in Participants With Relapsed or Refractory Large B-Cell Lymphoma

A Phase 1 interventional study of Cyclophosphamide and Fludarabine in Relapsed/Refractory Large B-cell Lymphoma, sponsored by Kite, A Gilead Company. Terminated at 10 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-03-04.

Primary conditionnone(registry's first term: Recurrence)No conditionIs this wrong?Recurrence describes something many studies share rather than a condition a study is about. The study names no condition we can place it under, so it is not compared with other studies by condition.

Sponsored by Kite, A Gilead Company (part of Gilead Sciences) · Phase 1, Interventional, and Treatment

Why this study was terminated
Development program terminated and the decision was not due to any safety concerns.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
6
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The primary objectives of this study are:

Phase 1: To evaluate the safety of sequenced therapy with lenzilumab and axicabtagene ciloleucel in participants with relapsed or refractory large B-cell lymphoma and identify the most appropriate dose of lenzilumab for Phase 2.

Phase 2: To evaluate the incidence of neurologic events with sequenced therapy given at the recommended Phase 2 dose (RP2D) of lenzilumab in participants with relapsed or refractory large B-cell lymphoma.

Read the detailed description

This study was intended to be a Phase 1/2, but the planned Phase 2 part has been canceled.

All participants who received an infusion of lenzilumab and axicabtagene ciloleucel will be provided the opportunity to transition to a separate long-term follow-up (LTFU) study, KT-US-982-5968.

02

Conditions studied

  • Relapsed/Refractory Large B-cell Lymphoma

Browse trials for

Keywords

  • Granulocyte Macrophage-Colony Stimulating Factor (GM-CSF)
  • GM-CSF antibody
  • Chimeric Antigen Receptor (CAR)
  • CD19
03

In context

Lead sponsor

Kite, A Gilead Company is the lead sponsor of 40 studies on the registry; 8 are open to participants now.

Of its 19 completed or terminated interventional studies of FDA-regulated products, 16 (84%) have results posted.

First submitted after Kite became part of Gilead Sciences.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Individuals with large B-cell lymphoma, including Diffuse large B-cell lymphoma (DLBCL) not otherwise specified, Primary mediastinal large B-cell lymphoma (PMBCL), High-grade B-cell lymphoma (HGBL), and DLBCL arising from Follicular lymphoma (FL)
  • Individuals must have disease after 2 or more , or chemorefractory disease defined as the following:

    • No response to first-line therapy, including the following:

      • Progressive disease (PD) as best response to first therapy
      • Stable disease (SD) as best response after ≥ 4 cycles of first-line therapy (eg, 4 cycles of rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone (R-CHOP)), with SD duration no longer than 6 months from the last dose of therapy
    • No response to ≥ 2 lines of therapy, including the following:

      • PD as best response to most recent therapy
      • SD as best response after ≥ 2 cycles of last line of therapy
  • Individuals must have received adequate prior therapy including at a minimum:

    • Anti-CD20 monoclonal antibody unless investigator determines that tumor is CD20 negative, and
    • An anthracycline-containing chemotherapy regimen
  • At least 1 according to the International Working Group Lugano Classification. Lesions that have been previously irradiated will be considered measurable only if progression has been documented following completion of radiation therapy.
  • Magnetic resonance imaging of the brain showing no evidence of central nervous system (CNS) lymphoma
  • (ECOG) performance status of 0 or 1
  • Individuals with a known medical history of tuberculosis or a risk for tuberculosis exposure require negative tuberculosis testing by either tuberculin skin test or interferon gamma release assay.
  • Adequate bone marrow function as evidenced by:

    • ≥ 1000/μL
    • ≥ 75,000/μL
    • Absolute lymphocyte count ≥ 100/μL
  • Adequate renal, hepatic, cardiac, and pulmonary function as evidenced by:

    • (Cockcroft-Gault) ≥ 60 mL/min
    • Serum or aspartate aminotransferase ≤ 2.5
    • Total ≤ 1.5 mg/dL, except in individuals with Gilbert's Syndrome
    • Cardiac ≥ 50% with no evidence of pericardial effusion as determined by echocardiogram (ECHO), and no clinically significant (ECG) findings
    • No clinically significant pleural effusion
    • Baseline oxygen saturation > 92% on room air

Key Exclusion Criteria:

  • History of Richter's transformation of chronic lymphocytic leukemia
  • stem cell transplant (SCT) within 6 weeks of planned axicabtagene ciloleucel infusion
  • History of allogeneic stem cell transplantation
  • Prior CD19 targeted therapy or prior CAR T cell therapy
  • History of pulmonary alveolar proteinosis (PAP)
  • History of severe, immediate reaction attributed to aminoglycosides
  • Known history of (HIV) infection, (HBsAg positive) or (HCV) (anti-HCV positive) infection. A history of hepatitis B or hepatitis C infection is permitted if the viral load is undetectable per quantitative polymerase chain reaction (PCR) and/or nucleic acid testing.
  • Individuals with detectable Cerebrospinal fluid (CSF) malignant cells, or , or with a history of CNS lymphoma, CSF malignant cells or brain metastases
  • History or presence of CNS disorder such as seizure disorder, cerebrovascular ischemia/hemorrhage, dementia, cerebellar disease, or any disease with CNS involvement

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
6 participants (actual)

Study arms

  • Experimental
    Lenzilumab and Axicabtagene Ciloleucel

    Phase 1: Participants will receive cyclophosphamide and fludarabine lymphodepleting chemotherapy followed by sequenced therapy of lenzilumab and axicabtagene ciloleucel on Day 0 to determine a recommended Phase 2 dose (RP2D) of lenzilumab. Phase 2: Participants will receive cyclophosphamide and fludarabine lymphodepleting chemotherapy followed by sequenced therapy of lenzilumab, at the RP2D, and axicabtagene ciloleucel on Day 0.

    Drug: Cyclophosphamide · Drug: Fludarabine · Biological: Lenzilumab · Biological: Axicabtagene Ciloleucel

Interventions

  • Administered according to package insert

  • Administered according to package insert

  • BiologicalLenzilumab

    Administered as an IV infusion

    Also known as: Humaneered® anti-human GM-CSF monoclonal antibody

  • A single infusion of chimeric antigen receptor (CAR) transduced autologous T cells administered intravenously.

    Also known as: Yescarta®

06

What researchers measure

Primary outcomes

  1. Phase 1: Percentage of Participants Experiencing Adverse Events (AEs) Defined as Dose Limiting Toxicities (DLTs) Related to Sequenced Therapy With Lenzilumab and Axicabtagene

    A DLT was defined as the following sequenced therapy-related events with onset within the first 28 days following lenzilumab and axicabtagene ciloleucel infusions: * Grade 4 neutropenia lasting longer than 21 days from the day of cell transfer * Grade 4 thrombocytopenia lasting longer than 28 days from the day of cell transfer * Any sequenced therapy-related AE requiring intubation, including Grade 4 encephalopathy requiring intubation for airway protection * Any sequenced therapy-related Grade 5 event

    Time frame: First infusion of lenzilumab and axicabtagene ciloleucel up to 28 days.

  2. Phase 2: Percentage of Participants Experiencing Grade 2 or Higher Neurologic Events Within 28 Days of Axicabtagene Ciloleucel Administration

    Time frame: Up to 28 days

Secondary outcomes

  1. Phase 1 and Phase 2: Percentage of Participants Experiencing Adverse Events

    Time frame: Enrollment through 3 months after lenzilumab and axicabtagene ciloleucel infusion.

  2. Phase 1 and Phase 2: Percentage of Participants Experiencing Serious Adverse Events

    Time frame: Enrollment through 3 months after lenzilumab and axicabtagene ciloleucel infusion.

  3. Phase 1 and Phase 2: Percentage of Participants Experiencing Cytokine Release Syndrome

    Time frame: Enrollment through 12 months after lenzilumab and axicabtagene ciloleucel infusion or until disease progression, whichever occurred first.

  4. Phase 1 and Phase 2: Percentage of Participants Experiencing Neurologic Events

    Time frame: Enrollment through 12 months after lenzilumab and axicabtagene ciloleucel infusion or until disease progression, whichever occurred first.

  5. Phase 1 and Phase 2: Complete Response (CR) Rate Per Internal Working Group (IWG) Lugano Classification as Determined by the Study Investigators

    CR rate: percentage of participants with CR (CMR;CRR). CMR: positron emission tomography(PET)5-point scale(5PS) scores of 1(no uptake above background), 2(uptake ≤ mediastinum), 3(uptake \> mediastinum but ≤ liver) with/without a residual mass); no new sites; and no evidence of fluorodeoxyglucose (FDG)-avid disease in bone marrow. CRR: target nodes/nodal masses regressed to ≤ 1.5 cm in longest transverse diameter (LDi) of a lesion; no extra lymphatic sites; absent non-measured lesion;organ enlargement regress to normal; no new sites; and bone marrow normal by morphology.

    Time frame: First infusion date axicabtagene ciloleucel to data cut off date of 09 May 2022 (maximum duration: 22.3 months).

  6. Phase 1 and Phase 2: Objective Response Rate (ORR) Per IWG Lugano Classification as Determined by Study Investigators

    ORR: Percentage of participants with CR(CMR;CRR) or PR(partial metabolic response(PMR);partial radiologic response (PRR)).CMR:PET 5PS scores of 1,2,3 with/without a residual mass;no new sites;no evidence of FDG-avid disease in bone marrow.CRR:target nodes/nodal masses regressed to ≤ 1.5 cm in LDi of a lesion;no extra lymphatic sites;absent non-measured lesion;organ enlargement regress to normal;no new sites;bone marrow normal by morphology.PMR:5PS scores of 4(uptake moderately higher than liver),or 5(uptake markedly higher than liver and/or new lesions),with reduced uptake compared to baseline and residual masses of any size;no new sites;residual update \> update in normal bone marrow but reduced compared with baseline.PRR:≥ 50% decrease in sum of the product of perpendicular diameters of up to 6 target measurable nodes and extranodal sites;absent/normal, regressed, but no increase of nonmeasured lesions;spleen regressed by \> 50% in length beyond normal;no new sites.

    Time frame: First infusion date axicabtagene ciloleucel to data cut off date of 09 May 2022 (maximum duration: 22.3 months).

  7. Phase 1 and Phase 2: Duration of Response (DOR) in Participants Who Experience an Objective Response Per IWG Lugano Classification as Determined by Study Investigators

    DOR is defined only for participants who experience an objective response after axicabtagene ciloleucel infusion and is the time from the first objective response to disease progression or death from any cause. Objective response is defined in outcome measure (OM) 7.

    Time frame: First infusion date axicabtagene ciloleucel to data cut off date of 09 May 2022 (maximum duration: 22.3 months).

  8. Phase 1 and Phase 2: Progression-Free Survival (PFS) Per IWG Lugano Classification as Determined by Study Investigators

    PFS is defined as the time from the axicabtagene ciloleucel infusion date to the date of disease progression per Lugano classification or death from any cause.

    Time frame: First infusion date axicabtagene ciloleucel to data cut off date of 09 May 2022 (maximum duration: 22.3 months).

  9. Phase 1 and Phase 2: Overall Survival (OS)

    OS is defined as the time from axicabtagene ciloleucel infusion to the date of death.

    Time frame: First infusion date axicabtagene ciloleucel to data cut off date of 09 May 2022 (maximum duration: 22.3 months).

  10. Phase 1 and Phase 2: Pharmacodynamics: Peak Serum Level of CXCL10, Granzyme B, IFN-gamma, IL-1 RA, IL-2, IL-6, IL-8, TNF Alpha, GM-CSF, and MCP-1

    Peak is defined as the maximum post-baseline level of the analyte from baseline to Week 4.

    Time frame: Baseline up to Week 4

  11. Phase 1 and Phase 2: Axicabtagene Ciloleucel Pharmacokinetics: Peak Level of Anti-CD19 CAR T Cells in Blood

    Peak is defined as the maximum number of CAR T cells in blood measured after the axicabtagene ciloleucel infusion.

    Time frame: Baseline up to Month 3

07

Results

Posted Mar 4, 2024

Participant flow

Participants were enrolled at study sites in the United States.

Participant flow — Overall Study
MilestonePhase 1/Cohort 1Phase 1/Cohort 2
Started33
Completed00
Not completed33
Withdrew: Death22
Withdrew: Rolled over to long-term follow-up study after study terminated11

Outcome measures

PrimaryPhase 1: Percentage of Participants Experiencing Adverse Events (AEs) Defined as Dose Limiting Toxicities (DLTs) Related to Sequenced Therapy With Lenzilumab and Axicabtagene

A DLT was defined as the following sequenced therapy-related events with onset within the first 28 days following lenzilumab and axicabtagene ciloleucel infusions: * Grade 4 neutropenia lasting longer than 21 days from the day of cell transfer * Grade 4 thrombocytopenia lasting longer than 28 days from the day of cell transfer * Any sequenced therapy-related AE requiring intubation, including Grade 4 encephalopathy requiring intubation for airway protection * Any sequenced therapy-related Grade 5 event

Time frame:
First infusion of lenzilumab and axicabtagene ciloleucel up to 28 days.
Reported as:
Number · percentage of participants
Phase 1: Percentage of Participants Experiencing Adverse Events (AEs) Defined as Dose Limiting Toxicities (DLTs) Related to Sequenced Therapy With Lenzilumab and Axicabtagene
percentage of participantsPhase 1/Cohort 1Phase 1/Cohort 2
Phase 1: Percentage of Participants Experiencing Adverse Events (AEs) Defined as Dose Limiting Toxicities (DLTs) Related to Sequenced Therapy With Lenzilumab and Axicabtagene00
PrimaryPhase 2: Percentage of Participants Experiencing Grade 2 or Higher Neurologic Events Within 28 Days of Axicabtagene Ciloleucel Administration
Time frame:
Up to 28 days

No measurements were reported for this outcome.

SecondaryPhase 1 and Phase 2: Percentage of Participants Experiencing Adverse Events
Time frame:
Enrollment through 3 months after lenzilumab and axicabtagene ciloleucel infusion.
Reported as:
Number · percentage of participants
Phase 1 and Phase 2: Percentage of Participants Experiencing Adverse Events
percentage of participantsPhase 1/Cohort 1Phase 1/Cohort 2
Phase 1 and Phase 2: Percentage of Participants Experiencing Adverse Events100100
SecondaryPhase 1 and Phase 2: Percentage of Participants Experiencing Serious Adverse Events
Time frame:
Enrollment through 3 months after lenzilumab and axicabtagene ciloleucel infusion.
Reported as:
Number · percentage of participants
Phase 1 and Phase 2: Percentage of Participants Experiencing Serious Adverse Events
percentage of participantsPhase 1/Cohort 1Phase 1/Cohort 2
Phase 1 and Phase 2: Percentage of Participants Experiencing Serious Adverse Events67100
SecondaryPhase 1 and Phase 2: Percentage of Participants Experiencing Cytokine Release Syndrome
Time frame:
Enrollment through 12 months after lenzilumab and axicabtagene ciloleucel infusion or until disease progression, whichever occurred first.
Reported as:
Number · percentage of participants
Phase 1 and Phase 2: Percentage of Participants Experiencing Cytokine Release Syndrome
percentage of participantsPhase 1/Cohort 1Phase 1/Cohort 2
Phase 1 and Phase 2: Percentage of Participants Experiencing Cytokine Release Syndrome6767
SecondaryPhase 1 and Phase 2: Percentage of Participants Experiencing Neurologic Events
Time frame:
Enrollment through 12 months after lenzilumab and axicabtagene ciloleucel infusion or until disease progression, whichever occurred first.
Reported as:
Number · percentage of participants
Phase 1 and Phase 2: Percentage of Participants Experiencing Neurologic Events
percentage of participantsPhase 1/Cohort 1Phase 1/Cohort 2
Phase 1 and Phase 2: Percentage of Participants Experiencing Neurologic Events10067
SecondaryPhase 1 and Phase 2: Complete Response (CR) Rate Per Internal Working Group (IWG) Lugano Classification as Determined by the Study Investigators

CR rate: percentage of participants with CR (CMR;CRR). CMR: positron emission tomography(PET)5-point scale(5PS) scores of 1(no uptake above background), 2(uptake ≤ mediastinum), 3(uptake \> mediastinum but ≤ liver) with/without a residual mass); no new sites; and no evidence of fluorodeoxyglucose (FDG)-avid disease in bone marrow. CRR: target nodes/nodal masses regressed to ≤ 1.5 cm in longest transverse diameter (LDi) of a lesion; no extra lymphatic sites; absent non-measured lesion;organ enlargement regress to normal; no new sites; and bone marrow normal by morphology.

Time frame:
First infusion date axicabtagene ciloleucel to data cut off date of 09 May 2022 (maximum duration: 22.3 months).
Reported as:
Number · percentage of participants
Phase 1 and Phase 2: Complete Response (CR) Rate Per Internal Working Group (IWG) Lugano Classification as Determined by the Study Investigators
percentage of participantsPhase 1/Cohort 1Phase 1/Cohort 2
Phase 1 and Phase 2: Complete Response (CR) Rate Per Internal Working Group (IWG) Lugano Classification as Determined by the Study Investigators67 (9 to 99)67 (9 to 99)
SecondaryPhase 1 and Phase 2: Objective Response Rate (ORR) Per IWG Lugano Classification as Determined by Study Investigators

ORR: Percentage of participants with CR(CMR;CRR) or PR(partial metabolic response(PMR);partial radiologic response (PRR)).CMR:PET 5PS scores of 1,2,3 with/without a residual mass;no new sites;no evidence of FDG-avid disease in bone marrow.CRR:target nodes/nodal masses regressed to ≤ 1.5 cm in LDi of a lesion;no extra lymphatic sites;absent non-measured lesion;organ enlargement regress to normal;no new sites;bone marrow normal by morphology.PMR:5PS scores of 4(uptake moderately higher than liver),or 5(uptake markedly higher than liver and/or new lesions),with reduced uptake compared to baseline and residual masses of any size;no new sites;residual update \> update in normal bone marrow but reduced compared with baseline.PRR:≥ 50% decrease in sum of the product of perpendicular diameters of up to 6 target measurable nodes and extranodal sites;absent/normal, regressed, but no increase of nonmeasured lesions;spleen regressed by \> 50% in length beyond normal;no new sites.

Time frame:
First infusion date axicabtagene ciloleucel to data cut off date of 09 May 2022 (maximum duration: 22.3 months).
Reported as:
Number · percentage of participants
Phase 1 and Phase 2: Objective Response Rate (ORR) Per IWG Lugano Classification as Determined by Study Investigators
percentage of participantsPhase 1/Cohort 1Phase 1/Cohort 2
Phase 1 and Phase 2: Objective Response Rate (ORR) Per IWG Lugano Classification as Determined by Study Investigators67 (9 to 99)100 (29 to 100)
SecondaryPhase 1 and Phase 2: Duration of Response (DOR) in Participants Who Experience an Objective Response Per IWG Lugano Classification as Determined by Study Investigators

DOR is defined only for participants who experience an objective response after axicabtagene ciloleucel infusion and is the time from the first objective response to disease progression or death from any cause. Objective response is defined in outcome measure (OM) 7.

Time frame:
First infusion date axicabtagene ciloleucel to data cut off date of 09 May 2022 (maximum duration: 22.3 months).
Reported as:
Median · Months
Phase 1 and Phase 2: Duration of Response (DOR) in Participants Who Experience an Objective Response Per IWG Lugano Classification as Determined by Study Investigators
MonthsPhase 1/Cohort 1Phase 1/Cohort 2
Phase 1 and Phase 2: Duration of Response (DOR) in Participants Who Experience an Objective Response Per IWG Lugano Classification as Determined by Study Investigators9.9 (NA to NA)12.1 (2.7 to NA)
SecondaryPhase 1 and Phase 2: Progression-Free Survival (PFS) Per IWG Lugano Classification as Determined by Study Investigators

PFS is defined as the time from the axicabtagene ciloleucel infusion date to the date of disease progression per Lugano classification or death from any cause.

Time frame:
First infusion date axicabtagene ciloleucel to data cut off date of 09 May 2022 (maximum duration: 22.3 months).
Reported as:
Median · Months
Phase 1 and Phase 2: Progression-Free Survival (PFS) Per IWG Lugano Classification as Determined by Study Investigators
MonthsPhase 1/Cohort 1Phase 1/Cohort 2
Phase 1 and Phase 2: Progression-Free Survival (PFS) Per IWG Lugano Classification as Determined by Study Investigators10.8 (0.9 to NA)13.0 (3.6 to NA)
SecondaryPhase 1 and Phase 2: Overall Survival (OS)

OS is defined as the time from axicabtagene ciloleucel infusion to the date of death.

Time frame:
First infusion date axicabtagene ciloleucel to data cut off date of 09 May 2022 (maximum duration: 22.3 months).
Reported as:
Median · Months
Phase 1 and Phase 2: Overall Survival (OS)
MonthsPhase 1/Cohort 1Phase 1/Cohort 2
Phase 1 and Phase 2: Overall Survival (OS)10.8 (4.6 to NA)13.0 (3.6 to NA)
SecondaryPhase 1 and Phase 2: Pharmacodynamics: Peak Serum Level of CXCL10, Granzyme B, IFN-gamma, IL-1 RA, IL-2, IL-6, IL-8, TNF Alpha, GM-CSF, and MCP-1

Peak is defined as the maximum post-baseline level of the analyte from baseline to Week 4.

Time frame:
Baseline up to Week 4
Reported as:
Median · pg/mL
Phase 1 and Phase 2: Pharmacodynamics: Peak Serum Level of CXCL10, Granzyme B, IFN-gamma, IL-1 RA, IL-2, IL-6, IL-8, TNF Alpha, GM-CSF, and MCP-1
pg/mLPhase 1/Cohort 1Phase 1/Cohort 2
CXCL102000.00 (1474.50 to 2000.00)809.40 (448.60 to 1298.10)
Granzyme B14.50 (9.20 to 44.20)11.80 (2.60 to 17.80)
IFN-gamma1238.30 (90.60 to 1426.00)45.70 (7.50 to 151.50)
IL-1 RA4984.00 (4038.00 to 6187.00)919.00 (701.00 to 1099.00)
IL-211.80 (6.30 to 22.70)18.20 (2.50 to 21.10)
IL-622.50 (8.00 to 976.00)13.10 (3.00 to 15.40)
IL-856.70 (12.90 to 75.70)31.50 (15.40 to 39.90)
TNF alpha5.50 (3.40 to 16.50)3.00 (1.70 to 3.30)
GM-CSF1.90 (1.90 to 1.90)1.90 (1.90 to 1.90)
MCP-11178.10 (1007.00 to 1300.00)866.80 (589.90 to 968.90)
SecondaryPhase 1 and Phase 2: Axicabtagene Ciloleucel Pharmacokinetics: Peak Level of Anti-CD19 CAR T Cells in Blood

Peak is defined as the maximum number of CAR T cells in blood measured after the axicabtagene ciloleucel infusion.

Time frame:
Baseline up to Month 3
Reported as:
Mean · cells/μL
Phase 1 and Phase 2: Axicabtagene Ciloleucel Pharmacokinetics: Peak Level of Anti-CD19 CAR T Cells in Blood
cells/μLPhase 1/Cohort 1Phase 1/Cohort 2
Phase 1 and Phase 2: Axicabtagene Ciloleucel Pharmacokinetics: Peak Level of Anti-CD19 CAR T Cells in Blood74.28 ± 97.6020.35 ± 15.12

Adverse events

Collected over Adverse Events: Enrollment through 3 months after lenzilumab and axicabtagene ciloleucel infusion. All-Cause Mortality: Enrollment up to 22.5 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Phase 1/Cohort 12/3 (66.7%)2/3 (66.7%)3/3 (100%)
Phase 1/Cohort 22/3 (66.7%)3/3 (100%)3/3 (100%)
Most frequent serious events
Showing 10 of 14
Most frequent serious events
EventPhase 1/Cohort 1Phase 1/Cohort 2
EncephalopathyNervous system disorders1/32/3
AnaemiaBlood and lymphatic system disorders1/30/3
PyrexiaGeneral disorders0/31/3
Covid-19Infections and infestations0/31/3
Covid-19 pneumoniaInfections and infestations1/31/3
PneumoniaInfections and infestations0/31/3
Platelet count decreasedInvestigations1/30/3
HyponatraemiaMetabolism and nutrition disorders1/30/3
Muscular weaknessMusculoskeletal and connective tissue disorders0/31/3
AphasiaNervous system disorders0/31/3
Most frequent other events
Showing 10 of 61
Most frequent other events
EventPhase 1/Cohort 1Phase 1/Cohort 2
NeutropeniaBlood and lymphatic system disorders3/31/3
Neutrophil count decreasedInvestigations3/32/3
Muscular weaknessMusculoskeletal and connective tissue disorders0/33/3
LymphadenopathyBlood and lymphatic system disorders0/32/3
Sinus tachycardiaCardiac disorders0/32/3
ConstipationGastrointestinal disorders0/32/3
NauseaGastrointestinal disorders2/31/3
FatigueGeneral disorders2/31/3
MalaiseGeneral disorders0/32/3
PyrexiaGeneral disorders2/32/3

Baseline characteristics

The Safety Analysis Set included all participants treated with any dose of axicabtagene ciloleucel and/or any dose of lenzilumab.

Age, Categorical
Age, Categorical(Participants)Phase 1/Cohort 1Phase 1/Cohort 2Total
<=18 years000
Between 18 and 65 years224
>=65 years112
Age, Continuous
Age, Continuous(years)Phase 1/Cohort 1Phase 1/Cohort 2Total
Mean62 ± 15.765 ± 10.264 ± 12.0
Sex: Female, Male
Sex: Female, Male(Participants)Phase 1/Cohort 1Phase 1/Cohort 2Total
Female000
Male336
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Phase 1/Cohort 1Phase 1/Cohort 2Total
Hispanic or Latino000
Not Hispanic or Latino336
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Phase 1/Cohort 1Phase 1/Cohort 2Total
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American000
White336
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(Participants)Phase 1/Cohort 1Phase 1/Cohort 2Total
United States336
08

Study locations

10 sites
  • Stanford University
    Palo Alto, California 94305, United States
  • Moffitt Cancer Center
    Tampa, Florida 33612, United States
  • Northwestern University
    Evanston, Illinois 60208, United States
  • Mayo Clinic
    Rochester, Minnesota 55905, United States
  • Roswell Park Cancer Institute
    Buffalo, New York 14263, United States
  • Columbia University Medical Center, New York-Presbyterian Hospital
    New York, New York 10032, United States
  • Levine Cancer Center
    Charlotte, North Carolina 28204, United States
  • Oregon Health & Science University
    Portland, Oregon 97239, United States
  • Vanderbilt University
    Nashville, Tennessee 37232, United States
  • MD Anderson Cancer Center
    Houston, Texas 77030, United States
09

References and documents

Publications

  • Kenderian, S. S., Oluwole, O. O., Mccarthy, P. L., Reshef, R., Shiraz, P., Ahmed, O., Le Gall, J., Nahas, M., Tang, L. And Neelapu, S. S. Zuma-19: A Phase 1/2 Multicenter Study of Lenzilumab Use With Axicabtagene Ciloleucel (Axi-Cel) In Patients (Pts) With Relapsed Or Refractory Large B Cell Lymphoma (R/R Lbcl). Blood 136(Supplement 1): 6-7, (2020). Conference Proceedings.
  • Olalekan O. Oluwole, MBBS, Saad S. Kenderian, MD, Parveen Shiraz, MD, Reem Karmali, MD, MSc, Ran Reshef, MD, MSc, Philip L. McCarthy, MD, Nilanjan Ghosh, MD, PhD, Aleksandr Lazaryan, MD, PhD, MPH, Simone Filosto, PhD, Soumya Poddar, PhD, Daqin Mao, PhD, Andrew Peng, MS, Adrian Kilcoyne, MD, MPH, Myrna Nahas, MD, Sattva S. Neelapu, MD. A Phase 1/2 Study of Axicabtagene Ciloleucel Plus Lenzilumab in Patients With Relapsed or Refractory Large B-Cell Lymphoma. American Society of Hemotology; Dec 10-13, 2022; New Orleans, LA. Abstract 4635

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at https://www.gileadclinicaltrials.com/transparency-policy/

Supporting information: Study protocol, Statistical analysis plan

Time frame: 18 months after study completion

Access criteria: A secured external environment with username, password, and RSA code.

Data sharing details ↗ · www.gileadclinicaltrials.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2020 to primary completion in Mar 2021, 9 months.

Results were first posted in Mar 2024, 2 years 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 17, 2020
First posted
Mar 19, 2020
StartActual
May 26, 2020
Primary completionActual
Mar 16, 2021
CompletionActual
Jul 27, 2022
Results first posted
Mar 4, 2024
Last update
Mar 4, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 4, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04314843
Collaborators
Humanigen, Inc.
Responsible party
Sponsor
First posted
Mar 19, 2020
Start date
May 26, 2020
Primary completion
Mar 16, 2021
Completion
Jul 27, 2022
Results posted
Mar 4, 2024
Last update
Mar 4, 2024

Study contacts

Kite Study Director
study director · Kite, A Gilead Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Lenzilumab · Axicabtagene ciloleucel

Start the discussion